Navigation Links
Madam Therapeutics Closes €1.1 Million Financing Round to Develop Novel Antibiotics Against Drug Resistant Bacteria
Date:8/29/2018

Madam Therapeutics, a privately-held biotech company that is developing a novel class of antibiotics inspired by the defense mechanisms of the human body, today announced the closing of its first financing round. The investment comes from a network of European business angels facilitated by Ekoy Investment Partners, De Investeerders Club and Investormatch.

The new funding will be used to continue and accelerate the clinical development of Madam Therapeutics’ lead candidate SAAP-148, by executing a first-in-men proof of concept study starting early next year and preparation of the following clinical phase II trial.

Lead candidate: SAAP-148
When a small subset of bacteria survives antibiotic treatment e.g. by mutations, an infection can get out of control fast. As these resilient microbes thrive, they can group together on a surface—like a wound or a medical device—and encase themselves in a slimy protective layer known as a biofilm. Such biofilm infections “are the really nasty things for patients,” says immunologist Peter Nibbering at Leiden University Medical Center in the Netherlands with whom Madam Therapeutics closely collaborates.

Madam Therapeutics and a team of esteemed Dutch scientists from o.a. Leiden University Medical Center (LUMC) and Amsterdam Medical Center(AMC) have developed a new antibiotic with improved characteristics to fight a broad spectrum of infections. In a recent editorial comment on the new compound on the website of the scientific journal Science, Dr Kim Lewis, a microbiologist at Northeastern University in Boston says that the candidate adds “an important piece … to the puzzle of creating a perfect antibiotic”.

Dr. Remko van Leeuwen, CEO of Madam Therapeutics, comments on this first financing round:
“Most of the antibiotic drugs currently in the worldwide clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions. Antimicrobial resistance is a global health emergency. There is an urgent need for more research and development for antibiotic-resistant infections, otherwise people will die from very simple infections”. Remko van Leeuwen is thrilled to welcome the group of investors to Madam Therapeutics. “The recent investment clearly represents a growing commitment and understanding from the investment community to the development of new antimicrobial agents and reflects the potential of our drug programs.”

Jaap Wieling, a spokesmen of the investor group says: “This funding will allow Madam Therapeutics to take important steps forward with its lead candidate SAAP-148. Where most traditional antibiotics have a slow acting mechanism of action, SAAP-148 kills the bacteria very fast by attacking them directly from the outside, puncturing the cell membrane and make it deflate. Now with the backing of this solid investor base, the seasoned team will be able to explore the full potential of its technology”.

Ron Byron, Partner at Ekoy invest that helped to successfully put together the investment group says: “From my experience in marketing of antibiotics, I am very much aware of growing need for new antibiotics. Unless antibacterial development is re-energised, there is a serious risk that a growing proportion of infections, especially in hospitals, will become effectively untreatable leading to many unnecessary casualties.”

About Madam Therapeutics
Madam Therapeutics is a privately held company from the Netherlands that is developing Synthetic Anti-Microbial and Anti-Biofilm Peptides (SAAPs) to combat resistant bacterial infections. Our SAAPs have a powerful and fast killing effect towards a very broad spectrum of bacteria and have a very favorable tolerance profile. Our SAAPs combine two characteristics essential for such new strategies: powerful killing of (resistant) bacteria and limited likelihood of emerging resistance. To date, Madam Therapeutics and her academic partners have raised a substantial amount of non-dilutive funding for the development of a family of over 300 unique SAAPs and a pipeline of SAAP based products for multiple infectious diseases.
Madam Therapeutics is currently actively fundraising for the next stages of clinical trials and broadening its pipeline of products, besides looking for co-development partners for further development and commercialization of its products.

For more information, please contact:
Remko van Leeuwen
CEO
+31 71 2040 105 Extension 100
press@madam-therapeutics.com
http://www.madam-therapeutics.com

Investor relations:
investors@madam-therapeutics.com

Read the full story at https://www.prweb.com/releases/madam_therapeutics_closes_1_1_million_financing_round_to_develop_novel_antibiotics_against_drug_resistant_bacteria/prweb15717600.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related medicine news :

1. Madame Munchie Wins the 2014 High Times Cannabis Cup Award for Best Medical Marijuana Edibles in San Francisco for their Artisanal Cannabis Macarons
2. Symbiomix Therapeutics Receives FDA Approval of Solosec™ (secnidazole) Oral Granules Following Four-Year Collaboration with Catalent
3. Thermo Fisher Scientific Enables Targeted Therapeutics by Utilizing Transcriptomics
4. NEW Ingredient: Euromed SA Partners with Biotherapeutics Inc. to Launch the First Abscisic Acid Nutritional Ingredient to Market
5. Innovations Series Explores Advances in Therapeutics for Treatment and Diagnosis of Disease
6. Open Therapeutics and AuthorAID to Cooperate on Advancing Scientific Knowledge
7. Blue Door Therapeutics Paving the Way to Treat the Opioid Epidemic with $2 Million Dollar Treatment Center in North Scottsdale
8. Coalition Duchenne Congratulates Capricor Therapeutics on Positive Six-Month Results from its Randomized CAP-1002 Phase I/II HOPE Clinical Trial in Duchenne
9. MAP and Lief Therapeutics Partner to Track Anxiety Real-time in Substance Use Disorder Populations
10. Just Biotherapeutics, Inc., Hangzhou Just Biotherapeutics, Ltd., and G-CON Manufacturing, Inc. Announce Collaboration on State of the Art Bioprocess Facility in China
11. Prof. Nishimura to Present Emerging Technologies for Evaluation of Biotherapeutics at Pittcon 2017 JAIMA Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2019)... ... November 21, 2019 , ... ... to North America’s long-term post-acute care and senior care industry, has named ... the close collaboration between Richter and PointClickCare on targeted training activities related ...
(Date:11/20/2019)... CHATTANOOGA, Tenn. (PRWEB) , ... November 20, 2019 ... ... Formulation on Human Organ Health Specific Biomarkers In Vitro Assays’” by Eileen Mary ... categories including Medical Biochemistry, Health, Fitness & Dieting, Religion & Spirituality, Family and ...
(Date:11/20/2019)... , ... November 20, 2019 , ... Promises Behavioral Health, ... to help clients stay on track with their recovery after initial care. The Rooted ... no extra cost to their clients. , The Rooted alumni program was created ...
(Date:11/20/2019)... , ... November 20, 2019 , ... ... Health Specific Biomarkers Using Cell Line Study” by Ariadne Esmene Afaganis has been ... Kingdom in many categories including Nervous System, Molecular Biology, Energy Healing, Public Health, ...
(Date:11/19/2019)... ... November 19, 2019 , ... ... interview with Experience Ancient Seas Founder Lisa Hall to discuss their ... that creates mineral-rich products that nourish skin with eighty-four trace minerals. These uniquely ...
Breaking Medicine News(10 mins):
(Date:11/19/2019)... ... 19, 2019 , ... Creative Safety Supply, Oregon’s premier retailer ... guide to industrial floor marking . , This comprehensive guide provides all ... paint, and signs. From creative applications to product recommendations and helpful tips, Creative ...
(Date:11/16/2019)... ... November 15, 2019 , ... October 29 ... candy at any time when more than usual is being consumed – is best ... peak. In doing so, the sugars and acids found in candy are more likely ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... publication of two double-blind, placebo-controlled human clinical trials using AstaZine® on brain health. ... three critical markers including feelings of depression, mental fatigue and overall mood state ...
Breaking Medicine Technology: